SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
IN PARTNERSHIP WITH TRUVETA
Webinar: AI for Faster, More Precise Real-World Research: Extracting Clinical Notes Data at Scale
In this webinar, we’ll explore how the Truveta Language Model (TLM)—a multi-modal AI model trained on EHR data—unlocks insights from clinical notes at scale. Watch now.
August 27, 2025
 · 
1 min read
 · 
BioSpace Insights
Image of Harvard University and pedestrian bridge on Charles River in Cambridge, Massachusetts
Labor market
Massachusetts R&D, Biomanufacturing Jobs Fell in ’24: Report
Massachusetts biopharma workforce growth was fairly flat last year, and R&D and manufacturing employment declined, according to a new MassBio report. BioSpace data further highlight challenges facing the state, showing roughly 2,300 people out of work in 2025 and jobs live on the website falling.
August 27, 2025
 · 
6 min read
 · 
Angela Gabriel
A pit crew working on a race car
Regulatory
The US Is Losing Its Biopharma Edge, Writes Former FDA Commissioner
Scott Gottlieb, who served as FDA commissioner during the first Trump administration, wrote in a JAMA editorial that China is speeding drugs to market and could potentially surpass the U.S. in the innovation game.
August 27, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Special edition
Deep Dive: Women in Biopharma
BioSpace did a deep dive into biopharma female executives who navigated difficult markets to lead their companies to high-value exits.
August 27, 2025
 · 
1 min read
 · 
Annalee Armstrong
Dashed line from pills isolated on white
Rare diseases
Amylyx Axes Drug Program for Rare Neurodegenerative Disorder
AMX0035—approved as Relyvrio in 2022 for amyotrophic lateral sclerosis but voluntarily pulled from the market last year—was unable to distinguish itself from placebo in a mid-to-late-stage trial of progressive supranuclear palsy.
August 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: A brain surrounded by falling pills
Neuroscience
Novartis, BioArctic Partner To Penetrate the Blood-Brain Barrier
Novartis has bet up to $772 million to gain access to BioArctic’s BrainTransporter platform, which was leveraged in a partnership with Eisai to produce Leqembi.
August 27, 2025
 · 
1 min read
 · 
Tristan Manalac
Contemporary art collage of target and hands with the megaphone on a ue background with copy space. Concept of reaching a goal and spreading.
Rare diseases
Regeneron Eyes 2026 Filing for siRNA Myasthenia Gravis Drug After Phase III Win
Regeneron’s cemdisiran, used alone or in combination with its complement inhibitor Veopoz, significantly improved activities of daily living in patients with generalized myasthenia gravis.  
August 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Pfizer's signage outside its office in Canada/iStock, JHVEPhoto
Layoffs
Pfizer Cuts 100 From Former Seagen HQ Amid ‘Digital Enablement and Automation’ Push
The layoffs will affect employees at Pfizer’s Bothell, Washington site, which previously served as the headquarters for Seagen before being acquired by the pharma for $43 billion.
August 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change
Eli Lilly drops a second Phase III readout for orforglipron; AbbVie committed to the psychedelic therapeutics space with the $1.2 billion acquisition of Gilgamesh’s depression asset; the CDC taps vaccine skeptic Retsef Levi to lead its COVID-19 immunization working group; and the FDA prioritizes overall survival in cancer drug development.
August 27, 2025
 · 
1 min read
 · 
Jef Akst
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS